Aishwarya Anand
Overview
Explore the profile of Aishwarya Anand including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
24
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Leng Q, Anand A, Mixson A
Molecules
. 2024 Dec;
29(23.
PMID: 39683699
Over 20 years have passed since siRNA was brought to the public's attention. Silencing genes with siRNA has been used for various purposes, from creating pest-resistant plants to treating human...
2.
Jain M, Anand A, Sharma N, Shamim M, Enioutina E
Nutrients
. 2024 Oct;
16(20).
PMID: 39458560
: Several randomized controlled trials (RCTs) have shown conflicting results on cortisol levels following probiotic administration in healthy and diseased populations. Previous analyses were inconclusive due to limited studies, and...
3.
Leng Q, He J, Anand A, Mixson A
Methods Mol Biol
. 2024 Jun;
2822:367-386.
PMID: 38907929
Transfection with mRNA has been considered superior to that with plasmids since the mRNA can be translated to a protein in the cytosol without entering the nucleus. One disadvantage of...
4.
Anand A, Hegde N, Chhabra P, Purohit J, Kumar R, Gupta A, et al.
Ann Hematol
. 2024 Apr;
103(6):2133-2144.
PMID: 38634917
Background: Empirical use of pharmacogenetic test(PGT) is advocated for many drugs, and resource-rich setting hospitals are using the same commonly. The clinical translation of pharmacogenetic tests in terms of cost...
5.
Leng Q, Anand A, Mixson A
Discov Med
. 2024 Mar;
36(182):448-456.
PMID: 38531786
Although Warburg discovered pH discrepancies between tumor and normal tissues nearly 100 years ago, developing therapies to take advantage of this concept was relatively slow for the first 70 years....
6.
Anand A, Shanmugam S, Veluswamy A
Indian J Pathol Microbiol
. 2024 Feb;
67(3):677-679.
PMID: 38391307
We report an unusual presentation of an orbital spindle cell hemangioma in a 40-year-old male, who noted sudden redness and swelling of the left eye on waking up. On examination,...
7.
Sharma S, Anand A, Taneja S, Sharma V, Bhatia A, Patil A, et al.
J Complement Integr Med
. 2023 Dec;
21(1):38-45.
PMID: 38140744
Objectives: Preclinical evidence is needed to assess drug-metabolite behaviour in compromised liver function for developing the best antitubercular treatment (ATT) re-introduction regimen in drug-induced liver injury (DILI). The pharmacokinetic behavior...
8.
Sharma S, Sharma V, Taneja S, Bhatia A, Anand A, Patil A, et al.
J Complement Integr Med
. 2023 Sep;
20(4):797-803.
PMID: 37732506
Objectives: The hepatoprotective properties of scopoletin have been explored in carbon tetrachloride (CCl4) induced liver injury but not in drug-induced liver injury (DILI) scenarios. Only N-acetyl-cysteine (NAC) has proven efficacy...
9.
Sharma S, Anand A, Verma N, Sharma V, Bhatia A, Patil A, et al.
J Pharm Bioallied Sci
. 2023 Sep;
15(3):139-145.
PMID: 37705856
Background: N-acetyl transferase 2 (NAT2) polymorphism testing could not see the light of success as a biomarker tool in tuberculosis management. Additionally, the antitubercular treatment (ATT) drug's reintroduction regimen variations...
10.
Sharma S, Sharma V, Taneja S, Bhatia A, Anand A, Banerjee D, et al.
J Pharm Bioallied Sci
. 2023 Sep;
15(3):146-151.
PMID: 37705855
Background: We investigated the pharmacokinetic behavior of pyrazinamide (PZA) and pyrazinoic acid (PA) in the presence of carbon-tetrachloride (CCl) plus antitubercular treatment (ATT) drug-induced liver injury (DILI) in rats. Methods:...